S. Auteri

Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review

L. Gensler, R. Caporali, E. Favalli, 2020, Therapeutic advances in musculoskeletal disease.

Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol

W. Maksymowych, M. Rudwaleit, T. Kumke, 2021, Arthritis Research & Therapy.

Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons

P. Mease, K. Fahrbach, B. Neupane, 2023, Rheumatology and Therapy.

Anti-LL37 Antibodies Are Present in Psoriatic Arthritis (PsA) Patients: New Biomarkers in PsA

B. Marinari, M. Falchi, A. Costanzo, 2018, Front. Immunol..

Native/citrullinated LL37-specific T-cells help autoantibody production in Systemic Lupus Erythematosus

B. Marinari, M. Falchi, P. Romero, 2020, Scientific Reports.

Certolizumab pegol treatment in axial spondyloarthritis mitigates fat lesion development: 4-year post-hoc MRI results from a phase 3 study

J. Braun, X. Baraliakos, T. Nurminen, 2021, Rheumatology.

Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study

A. Deodhar, L. Gensler, W. Maksymowych, 2022, RMD Open.